The late trading rose sharply, and the pharmaceutical sector once again became the "sweet pastry" of institutions under the high prosperity of the industry Post date May 6, 2022 — 18:35 Post Lock Read More Qianyuan Pharmaceutical: The company has a drug approval for silybin meglumine tablets, which can be used for the adjuvant treatment of acute and chronic hepatitis, initial cirrhosis, and toxic liver damage Post date April 29, 2022 — 18:22 Post Lock Read More Qianyuan Pharmaceutical: At present, the daily testing capacity of the subsidiary Wuxi United Likang for the new crown can reach 5,000 tubes_Oriental Fortune Network Post date April 29, 2022 — 18:21 Post Lock Read More
Qianyuan Pharmaceutical: The company has a drug approval for silybin meglumine tablets, which can be used for the adjuvant treatment of acute and chronic hepatitis, initial cirrhosis, and toxic liver damage Post date April 29, 2022 — 18:22 Post Lock Read More Qianyuan Pharmaceutical: At present, the daily testing capacity of the subsidiary Wuxi United Likang for the new crown can reach 5,000 tubes_Oriental Fortune Network Post date April 29, 2022 — 18:21 Post Lock Read More
Qianyuan Pharmaceutical: At present, the daily testing capacity of the subsidiary Wuxi United Likang for the new crown can reach 5,000 tubes_Oriental Fortune Network Post date April 29, 2022 — 18:21 Post Lock Read More